Mosquito-borne Diseases

Current Problems in Pediatric and Adolescent Health Care

Volumn 39, Issue 4, 2009, Pages 97-140

  Tolle, Michael A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMODIAQUINE; ANTIFILARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CLINDAMYCIN; DENGUE VACCINE; DEXTRAN 70; DIETHYLCARBAMAZINE; DIHYDROARTEMISININ; DOXYCYCLINE; FANSIDAR; HETASTARCH; IVERMECTIN; JAPANESE ENCEPHALITIS VACCINE; MALARIA VACCINE; MANNITOL; MEFLOQUINE; METHYLPREDNISOLONE; PRIMAQUINE; QUINIDINE; QUINIDINE GLUCONATE; QUININE; SA 14 14 2; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YELLOW FEVER VACCINE;

AEDES AEGYPTI; ANEMIA; ARTICLE; BED NET; BLOOD SMEAR; BLOOD TRANSFUSION; CHIKUNGUNYA ALPHAVIRUS; CHILD HEALTH; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DENGUE; DRUG MEGADOSE; ENCEPHALOMYELITIS; EPIDEMIC; EPIDEMIC ENCEPHALITIS; FILARIASIS; GEOGRAPHIC DISTRIBUTION; HEARING LOSS; HEMOLYSIS; HEMORRHAGIC FEVER; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; INSECT BITE; LOADING DRUG DOSE; MALARIA; MALARIA FALCIPARUM; MORTALITY; MOSQUITO; NEUTROPENIA; NONHUMAN; PARASITE VIRULENCE; PARASITOSIS; PLASMODIUM; VIRUS INFECTION; WEST NILE FLAVIVIRUS; YELLOW FEVER; ZOOLOGY;

ANIMALS; ARBOVIRUS INFECTIONS; CULICIDAE; DENGUE; ENCEPHALITIS, JAPANESE; FILARIASIS; HUMANS; INSECT VECTORS; MALARIA; WEST NILE FEVER; YELLOW FEVER;

EID: 62649174603     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cppeds.2009.01.001     Document Type: Article

References (199)

1. Reiter P. Climate change and mosquito-borne disease. Environ Health Perspect 109 S1 (2001) 141-161
2. White N.J. Malaria. In: Cook G.C., and Zumla A.I. (Eds). Manson's Tropical Diseases. 21st Edition (2004), Elsevier, London, England
3. Milner D.A., Montgomery J., Seydel K.B., and Rogerson S.J. Severe malaria in children and pregnancy: an update and perspective. Trends Parasitol 24 12 (2008) 590-595
4. World Health Organization. Malaria Treatment Guidelines. Accessed January 9, 2009. http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
5. U.S. Centers for Disease Control and Prevention. Yellow fever. In: Arguin P.M., Kozarsky P.E., and Reed C. (Eds). Health information for international travel, 2008 (2007), Centers for Disease Control and Prevention, Atlanta
6. World Health Organization. Dengue, dengue hemorrhagic fever and dengue shock syndrome in the context of the integrated management of childhood illness. Accessed January 9, 2009 (2005). http://whqlibdoc.who.int/hq/2005/WHO_FCH_CAH_05.13_eng.pdf
7. Mackenzie J.S., Gubler D.J., and Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis. West Nile and dengue viruses. Nat Med 10 12 (2004) S98-S109
8. World Health Organization. Management of Severe Malaria: a practical handbook. Accessed January 9, 2009 (2000). http://www.searo.who.int/LinkFiles/Malaria_Mgmtseveremalaria2.pdf
9. Jones G., Steketee R.W., Black R.E., Bhutta Z.A., Morris S.S., and Bellagio Child Survival Study Group. How many child deaths can we prevent this year?. Lancet 362 (2003) 65-71
10. Fegan G.W., Noor A.M., Akhwale W.S., Cousens S., and Snow R.W. Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet 370 (2007) 1035-1039
11. Is malaria eradication possible?. Lancet 370 (2007) 1459
12. Halstead S.B. Dengue. Lancet 370 (2007) 1644-1652
13. Campbell G.L., Marfin A.A., Lanciotti R.S., and Gubler D.J. West Nile virus. Lancet Infect Dis 2 (2002) 519-529
14. Pialoux G., Gauzere B., Jaureguiberry S., and Strobel M. Chikungunya, an epidemic arbovirus. Lancet Infect Dis 7 (2007) 319-327
15. Gould E.A., and Solomon T. Pathogenic flaviviruses. Lancet 371 (2008) 500-509
16. Oya A., and Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med 14 4 (2007) 259-268
17. The Global Alliance to Eliminate Lymphatic Filariasis website. Accessed January 9, 2009. www.filariasis.org
18. White G.B. Medical acarology and entomology: mosquitoes. In: Cook G.C., and Zumla A.I. (Eds). Manson's Tropical Diseases. 21st Edition (2004), Elsevier, London, England
19. Gubler D.J. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Am J Trop Med Hyg 40 6 (1989) 571-578
20. Afrane Y.A., Little T.J., Lawson B.W., Githeko A.K., and Yan G. Deforestation and vectorial capacity of Anopheles gambiae giles mosquitoes in malaria transmission. Emerg Infect Dis 14 10 (2008) 1533-1538
21. Baird J.K. Effectiveness of antimalarial drugs. N Engl J Med 352 (2005) 1565-1577
22. Cox-Singh J., Davis T.M., Lee K.S., Shamsul S.S., Matusop A., Ratnam S., et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life-threatening. Clin Infect Dis 46 (2008) 165-171
23. Alsop Z. Malaria returns to Kenya's highlands as temperatures rise. Lancet 370 (2007) 925-926
24. Stauffer W., and Fischer P.R. Diagnosis and treatment of malaria in children. Clin Infect Dis 37 (2003) 1340-1348
25. World Health Organization. A strategic framework for malaria prevention and control during pregnancy in the Africa region (2004), World Health Organization Regional Office for Africa. http://www.afro.who.int/malaria/publications/malaria_in_pregnancy_092004.pdf Accessed January 9, 2009 at: http://www.afro.who.int/malaria/publications/malaria_in_pregnancy_092004.pdf.
26. Parise M.E., Ayisi J.G., Nahlen B.L., Schultz L.J., Roberts J.M., Misore A., et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 59 (1998) 813-822
27. Hamer D.H., Mwanakasale V., MacLeod W.B., Chalwe V., Mukwamataba D., Champo D., et al. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis 196 (2007) 1585-1594
28. Vallely A., Vallely L., Changalucha J., Greenwood B., and Chandramohan D. Intermittent preventive treatment for malaria in pregnancy in Africa: what's new, what's needed?. Malaria J 6 (2007) 16-28
29. Chen L.H., Wilson M.E., and Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA 296 18 (2006) 2234-2244
30. Fischer P.R., and Bialek R. Prevention of malaria in children. Travel Med 34 (2002) 493-498
31. Freedman D.O. Malaria prevention in short-term travelers. N Engl J Med 359 (2008) 603-612
32. Griffith K.S., Lewis L.S., Mali S., and Parise M.E. Treatment of malaria in the United States-a systematic review. JAMA 297 20 (2007) 2264-2277
33. Tijtra E., Anstey N.M., Sugiarto P., Warikar N., Kenangalem E., Karyana M., et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua Indonesia. PLoS Med 5 (2008) e128
34. Genton B., D'Acremont V., Rare L., Baea K., Reeder J.C., Alpers M.P., et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study in Papua New Guinea. PLoS Med 5 (2008) e127
35. Beare N.A., Taylor T.E., Harding S.P., Lewallen S., and Molyneux M.E. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 75 5 (2006) 790-797
36. Beare N.A., Southern C., Chalira C., Taylor T.E., Molyneux M.E., and Harding S.P. Prognostic significance and course of retinopathy in children with severe malaria. Arch Ophthalmol 122 (2004) 1141-1147
37. Mwangi T.W., Ross A., Snow R.W., and Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 191 (2005) 1932-1939
38. Font F., Alonso Gonzalez M., Nathan R., Kimario J., Lwilla F., Ascaso C., et al. Diagnostic accuracy and case management of clinical malaria in the primary health services of a rural area in south-eastern Tanzania. Trop Med Int Health 6 (2001) 423-428
39. Reyburn H., Mbatia R., Drakeley C., Carneiro I., Mwakasungula E., Mwerinde O., et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 329 (2004) 1212
40. McMorrow M.L., Masanja M.I., Abdulla S.M., Kahigwa E., and Kachur S.P. Challenges in routine implementation and quality control of rapid diagnostic tests for malaria-Rufiji District, Tanzania. Am J Trop Med Hyg 79 3 (2008) 385-390
41. Lalloo D.G., Shingadia D., Pasvol G., Chiodini P.L., Whitty C.J., Beeching N.J., et al. UK malaria treatment guidelines. J Infect 54 (2007) 111-121
42. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev 15 (2002) 66-78
43. Reyburn H., Mbakilwa H., Mwangi R., Mwerinde O., Olomi R., Drakeley C., et al. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomized trial. BMJ 334 (2007) 403-409
44. Harvey S.A., Jennings L., Chinyama M., Masaninga F., Mulholland K., and Bell D.R. Improving community health worker use of malaria rapid diagnostic tests in Zambia: package instructions, job aid job aid-plus-training. Malaria J 7 (2008) 160-171
45. Mens P., Spieker N., Omar S., Heijnen M., Schallig H., and Kager P.A. Is molecular biology the best alternative for diagnosis of malaria to microscopy?. A comparison between microscopy, antigen detection and molecular tests in rural Kenya and urban Tanzania. Trop Med Int Health 12 2 (2007) 238-243
46. Mayxay M., Pukritayakamee S., Chotivaninch K., Looareesuwan S., and White N.J. Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg 95 (2001) 179-182
47. Rosenthal P.J. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 358 (2008) 1829-1836
48. Dondorp A., Nosten F., Stepniewska K., Day N., and White N. Artesunate versus quinine for the treatment of severe falciparum malaria: a randomized trial. Lancet 366 (2005) 717-725
49. Jones K.L., Donegan S., and Lalloo D.G. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 4 (2007) CD005967
50. Toovey S., and Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98 (2004) 261-269
51. World Health Organization. Malaria vector control and personal protection. Accessed January 9, 2009 (2006). http://www.who.int/malaria/docs/WHO-TRS-936s.pdf
52. World Health Organization. Indoor residual spraying: Use of indoor residual spraying for scaling up global malaria control and elimination. Accessed January 9, 2009 (2006). http://www.who.int/malaria/docs/IRS/IRS-position.pdf
53. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2 (2004) CD000363
54. Noor A.M., Amin A.A., Akhwale W.S., and Snow R.W. Increasing covereage and decreasing inequity in insecticide-treated bed net use among rural Kenyan children. PLoS Med 4 (2007) 1341-1348
55. Minakawa N., Dida G.O., Sonye G.O., Futami K., and Kaneko S. Unforeseen misuses of bed nets in fishing villages along Lake Victoria. Malaria J 7 (2008) 165-170
56. Gamble C., Ekwaru P.J., Garner P., and ter Kuile F.O. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomized controlled trials. PLoS Med 4 3 (2007) 0506-0515
57. Schhwarz N.G., Adegnika A.A., Breitling L.P., Gabor J., Agnandi S.T., Newman R.D., et al. Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis 47 (2008) 1017-1025
58. Ayisi J.G., van Ejik A.M., ter-Kuile F.O., Kolczak M.S., Otieno J.A., Misore A.O., et al. The effect of dual infection with HIV and malaria on pregnancy outcomes in western Kenya. AIDS 17 (2003) 585-594
59. Brahmbhatt H., Sullivan D., Kigozi G., Askin F., Wabwire-Mangenm F., Serwadda D., et al. Association of HIV and Malaria with mother-to-child transmission, birth outcomes, and child mortality. J Acquir Immune Defic Syndr Hum Retrovirol 47 (2008) 472-476
60. d'Alessandro U.D., and ter Kuile F.O. Amodiaquine, malaria, pregnancy: the old new drug. Lancet 368 (2006) 1306-1307
61. Schultz L.J., Steketee R.W., Macheso A., Kazembe P., Chitsulo L., and Wirima J.J. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 51 (1994) 515-522
62. Cisse B., Sokhna C., Boulanger D., Milet J., Ba E., Richardson K., et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomized, placebo-controlled, double-blind trial. Lancet 367 (2006) 659-667
63. Gimnig J.E., MacArthur J.R., M'bang'ombe M., Kramer M.H., Chizani M., Stern R.S., et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 74 (2006) 738-743
64. Geerligs P.D., Brabin B.J., and Eggelete T.A. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ 81 (2003) 205-216
65. Sokhna C., Cisse B., Ba E.H., Milligan P., Hallett R., Sutherland C., et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One 1 (2008) 1-9
66. Ntab B., Cisse B., Boulanger D., Sokhna C., Targett G., Lines J., et al. Impact of intermittent preventive anti-malarial treatment on the growth and nutritional status of preschool children in rural Senegal (West Africa). Am J Trop Med Hyg 77 3 (2007) 411-417
67. Clarke S.E., Jukes M.C., Njagi J.K., Khasakhala L., Cundill B., Otido J., et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 127-138
68. Schellenberg D., Menendez C., Aponte J.J., Kahigwa E., Tanner M., et al. Intermittent preventive antimalarial treatment for Tanzanian infants; follow-up to age 2 years of a randomized, placebo-controlled trial. Lancet 365 (2005) 1481-1483
69. Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants. Assessment of the role of intermittent preventive treatment for malaria in infants: letter report (2008), National Academies Press. http://www.nap.edu/catalog.php?record_id=12180 Accessed January 9, 2009 at http://www.nap.edu/catalog.php?record_id=12180.
70. Maire N., Tediosi F., Ross A., and Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med 75 Suppl 2 (2006) 111-118
71. Vanderberg J.P. Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine 27 1 (2009) 2-9
72. Girard M.P., Reed Z.H., Friede M., and Kieny M.P. A review of human vaccine research and development: malaria. Vaccine 25 (2007) 1567-1580
73. Tetteh K., and Polley S.D. Progress and challenges towards the development of malaria vaccines. Biodrugs 21 6 (2007) 357-373
74. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02A malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomized trial. Lancet 358 (2001) 1927-1934
75. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of RTS,S/AS02A malaria vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 364 (2004) 1411-1420
76. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized-controlled trial. Lancet 366 (2005) 2012-2018
77. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 370 (2007) 1543-1551
78. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185 6 (2002) 820-827
79. Epstein J.E. What will a partially protective malaria vaccine mean to mothers in Africa?. Lancet 370 (2007) 1523-1524
80. Rafikov M., Bevilacqua L., and Wyse A.P.P. Optimal control strategy of malaria vector using genetically modified mosquitoes. J Theor Biol (2008) doi:10.1016/j.jtbi.2008.08.006.
81. Helinski M.E.H., Hassan M.M., El-Motasim W.E., Malcolm C.A., Knols B.G.J., and El-Sayed B. Towards a sterile insect technique field release of Anopheles arabiensis mosquitoes in Sudan: irradiation, transportation, and field cage experimentation. Malaria J 7 (2008) 65-74
82. Bryan C.S., Moss S.W., and Kahn R.J. Yellow fever in the Americas. Infect Dis Clin North Am 18 (2004) 275-292
83. Staples J.E., and Monath T.P. Yellow fever: 100 years of discovery. JAMA 300 8 (2008) 960-962
84. Klempner M.S., Unnasch T.R., and Hu L.T. Taking a bite out of vector-transmitted infectious diseases. N Engl J Med 356 25 (2007) 2567-2569
85. Muller P., Warr E., Stevenson B.J., Pignatelli P.M., Morgan J.C., Steven A., et al. Field-caught permethrin-resistant Anopheles gambiae overexpress CYP6P3, a P450 that metabolises pyrethroids. PLoS Genet 4 11 (2008) e1000286
86. World Health Organization. The use of DDT in malaria vector control: WHO position statement. Accessed January 9, 2009 (2007). http://www.who.int/malaria/docs/IRS/DDT/DDTposition.pdf
87. Morrison A.C., Zielinski-Gutierrez E., Scott T.W., and Rosenberg R. Defining challenges and proposing solutions for control of Aedes aegypti. PLoS Med 5 3 (2008) e68
88. Kay B., and Nam V.S. New strategy against Aedes aegypti in Vietnam. Lancet 365 (2005) 613-617
89. Hayes E.B., and O'Leary D.R. West Nile virus: a pediatric perspective. Pediatrics 113 5 (2004) 1375-1381
90. American Academy of Pediatrics. Follow safety precautions when using DEET on children. Accessed January 9, 2009 (2003). http://aapnews.aappublications.org/cgi/content/full/e200399v1
91. U.S. Centers for Disease Control and Prevention. Malaria. In: Arguin P.M., Kozarsky P.E., and Reed C. (Eds). Health information for international travel, 2008 (2007), Centers for Disease Control and Prevention, Atlanta (GA)
92. World Health Organization. Malaria. In: Wilder-Smith A. (Ed). International travel and health, 2008 (2008), World Health Organization, Geneva
93. Borrmann S., Faucher J.F., Bagaphou T., Missinou M.A., Binder R.K., Pabisch S., et al. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clin Infect Dis 37 (2003) 1441-1447
94. Barrett A., and Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 52 (2007) 209-229
95. World Health Organization. The Immunological Basis for Immunization Series. Module 8: Yellow Fever. Accessed January 9, 2009 (1993). http://www.who.int/vaccines-documents/DocsPDF-IBI-e/mod8_e.pdf
96. Ellis B.R., and Barrett A.D. The enigma of yellow fever in East Africa. Rev Med Virol 18 5 (2008) 331-346
97. Gould E.A., de Lamballerie X., Zanotto P.M., and Holmes E.C. Origins, evolution, and vector/host coadaptions within the genus Flavivirus. Adv Virus Res 59 (2003) 277-314
98. Reed W., Carroll J., and Agramonte A. The etiology of yellow fever: an additional note. JAMA 36 8 (1901) 431-440
99. Van der Stuyft P., Gianella A., Pirard M., Cespedes J., Lora J., Peredo C., et al. Urbanisation of yellow fever in Santa Cruz. Bolivia. Lancet 353 (1999) 1558-1562
100. U.S. Centers for Disease Control and Prevention. Outbreak notice-Yellow fever in Paraguay-updated, 13 June 2008. Accessed December 1, 2008. http://www.cdc.gov/travel/contentYellowFeverParaguay.aspx
101. Broom A.K., Smith D.W., Hall R.A., Johansen C.A., and MacKenzie J.S. Arbovirus infections. In: Cook G.C., and Zumla A.I. (Eds). Manson's Tropical Diseases. 21st Edition (2004), Elsevier, London, England
102. Weir E., and Haider S. Yellow fever: readily prevented but difficult to treat. CMAJ 170 13 (2004) 1909-1910
103. Chao D., Davis B., and Chang G. Development of multiplex real-time reverse transcriptase PCR assays for detecting eight medically important flaviviruses in mosquitoes. J Clin Microbiol 45 2 (2007) 584-589
104. Jackson G.W., McNichols R.J., Fox G.E., and Wilson R.C. Toward universal Flavivirus identification by mass cataloging. J Mol Diagn 10 2 (2008) 135-141
105. Sampath A., and Padmanabhan R. Molecular targets for flavivirus drug discovery. Antivir Res 81 1 (2009) 6-15
106. World Health Organization. Yellow fever vaccine. Accessed January 9, 2009. www.who.int/vaccines/en/yellowfever.shtml
107. Orozco J. Defeating dengue: a difficult task ahead. Bull World Health Organ 85 10 (2007) 737-738
108. Monath T.P. Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med 357 (2007) 2222-2225
109. Barnett E.D., Wilder-Smith A., and Wilson M.E. Yellow fever vaccines and international travelers. Exp Rev Vacc 7 5 (2008) 579-587
110. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 26 (2008) 6077-6082
111. World Health Organization. Vaccine-preventable diseases and vaccines. In: Wilder-Smith A. (Ed). International travel and health, 2008 (2008), World Health Organization, Geneva
112. Poland J.D., Calisher C.H., and Monath T.P. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59 (1981) 895-900
113. World Health Organization. Mali: 6 million vaccinated against yellow fever. Accessed January 9, 2009 (2008). www.who.int/features/2008/mali_vaccine/en/
114. Ministerio da Saude, Brasil. Epizootia de primates por febre amarela no Noroests do Estado do Rio Grande do Sul. Accessed January 9, 2009 (2008). http://portal.saude.gov/br/portal/arquivos/pdf/epizootia_primatas_fa_2008.pdf
115. Pan American Health Organization. Final statement by the Pan American Health Organization/World Health Organization (PAHO/WHO) on investigation of serious adverse events in Peru following receipt of yellow fever vaccine produced by Bio-Manguinhos, Brazil. Accessed January 9, 2009 (2008). http://www.paho.org/English/AD/FCH/IM/PAHO_WHOStatement_YellowFever_11Aug08.pdf
116. Gubler D.J. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?. Comp Immunol Microbiol Infect Dis 27 (2004) 319-330
117. Hung N.T., Lan N.T., Lei H.Y., Lin Y.S., Lien L.B., Huang K.J., et al. Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome. Am J Trop Med Hyg 74 4 (2006) 684-691
118. Teixeira M.G., Costa M.C., Coehlo G., and Barreto M.L. Recent shift in age pattern of dengue hemorrhagic fever, Brazil. Emerg Infect Dis 14 10 (2008) 1663
119. Shepard D.S., Suaya J.A., Halstead S.B., Nathan M.B., Gubler D.J., Mahoney R.T., et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22 (2004) 1275-1280
120. Pan American Health Organization. Dengue in the Americas: the epidemics of 2000. Epidemiol Bull 21 (2000) 4-8
121. Pan American Health Organization. 2008: Number of reported cases of dengue and dengue hemorrhagic fever (DHF), region of the Americas. Accessed January 9, 2009. http://www.paho.org/english/ad/dpc/cd/dengue-cases-2008.htm
122. Wilder-Smith A., and Schwartz E. Dengue in travelers. N Engl J Med 353 9 (2005) 924-932
123. Guzman M.G., and Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol 27 (2003) 1-13
124. Hung L.T., and Lan N.T. Improvement of case management: a key factor to reduce case-fatality rate of dengue hemorrhagic fever in southern Vietnam. Dengue Bull 22 (2003) 144-148
125. Bandyopadhyay S., Lum L.C., and Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue hemorrhagic fever. Trop Med Int Health 11 8 (2006) 1238-1255
126. Guzman M.G., Kouri G., Diaz M., Llop A., Vazquez S., Gonzalez D., et al. Dengue, one of the great emerging health challenges of the 21st Century. Exp Rev Vacc 3 (2004) 511-520
127. Phuong C., Nhan N., Kneen R., Thuy P., Thien C., Nga N., et al. Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the World Health Organization classification scheme useful?. Am J Trop Med Hyg 70 2 (2004) 172-179
128. Balmaseda A., Hammond S., Perez M., Cuadra R., Solano S., Rocha J., et al. Short report: Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Trop Med Hyg 73 6 (2005) 1059-1062
129. Colbert J.A., Gordon A., Roxelin R., Silva S., Silva J., Rocha C., et al. Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J 26 (2007) 850-852
130. Srikiatkhachorn A., Krautrachue A., Ratanaprakarn W., Wongtapradit L., Nithipanya N., Kalayanarooj S., et al. Natural history of plasma leakage in dengue hemorrhagic fever, a serial ultrasonographic study. Pediatr Infect Dis J 26 (2007) 283-290
131. Tantracheewathorn T., and Tantracheewathorn S. Risk factors of dengue shock syndrome in children. J Med Assoc Thai 90 2 (2007) 272-277
132. Chacko B., and Subramanian G. Clinical, laboratory and radiological parameters in children with dengue fever and predictive factors for dengue shock syndrome. J Trop Pediatr 54 2 (2008) 137-140
133. Restrepo B., Ramirez R.E., Arboleda M., Alvarez G., Opsina M., and Diaz F. Serum levels of cytokines in two ethnic groups with dengue virus infection. Am J Trop Med Hyg 79 5 (2008) 673-677
134. LaFleur C., Granados J., Vargas-Alarcon G., Ruiz-Morales J., Villareal-Garza C., Higuera L., et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol 63 11 (2002) 1039-1044
135. Soundravally R., and Hoti S.L. Immunopathogenesis of dengue hemorrhagic fever and shock syndrome: role of TAP and HPA gene polymorphism. Hum Immunol 68 12 (2007) 973-979
136. Soundravally R., and Hoti S.L. Polymorphisms of TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection. Scand J Immunol 67 6 (2008) 618-625
137. Fink J., Gu F., and Vasudevan S. Role of T cells, cytokines and antibody in dengue fever and dengue hemorrhagic fever. Rev Med Virol 16 (2006) 263-275
138. Kouri G., Guzman M.G., and Bravo J. Hemmorhagic dengue in Cuba: history of an epidemic. Bull Pan Am Health Organ 20 (1986) 24-30
139. Guzman M.G., Kouri G., Bravo J., Valdes L., Vazquez S., and Halstead S.B. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 7 3 (2003) 231-232
140. Pelaez O., Guzman M.G., Kouri G., Perez R., San Martin J.L., Vazquez S., et al. Dengue 3 epidemic. Havana, 2001. Emerg Infect Dis 10 4 (2004) 719-722
141. Halstead S.B., Lan N.T., Myint T.T., Shwe T.N., Nisalak A., Kalyanarooj S., et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 8 12 (2002) 1474-1479
142. Guzman M.G., and Kouri G.P. Dengue: an update. Lancet Infect Dis 185 (2002) 1213-1221
143. Dussart P., Petit L., Labeau B., Bremand L., Leduc A., Moua D., et al. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoS Neglected Trop Dis 2 8 (2008) e280
144. Wichmann O., Lauschke A., Frank C., Shu P.Y., Niedrig M., Huang J.H., et al. Dengue antibody presence in German travelers. Emerg Infect Dis 11 (2005) 762-765
145. Dussart P., Labeau B., Lagathu G., Louis P., Nunes M.R., Rodrigues S.G., et al. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clin Vaccine Immunol 13 (2006) 1185-1189
146. Kumarasamy V., Wahab A.H., Chua S.K., Hassan Z., Chem Y.K., Mohamad M., et al. Evaluation of a commercial dengue NS1 antigen-capture ELISA for laboratory diagnosis of acute dengue virus infection. J Virol Methods 140 (2007) 75-79
147. Wilde H., and Suankratay C. There is a need for antigen-based rapid diagnostic tests to identify common acute tropical illnesses. J Travel Med 14 4 (2007) 254-258
148. Wills B.A., Dung N.M., Loan H.T., Tam D.T., Thuy T.T., Minh L.T., et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 353 (2005) 877-889
149. Guzman M.G., Kouri G., and Halstead S.B. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics?. Lancet 355 (2000) 1902-1903
150. Ranjit S., Kissoon N., and Jayakumar I. Aggressive management of dengue shock syndrome may decrease mortality rate: a suggested protocol. Pediatr Crit Care Med 6 4 (2005) 412-419
151. Soni A., Chugh K., Sachdev A., and Gupta D. Management of dengue fever in ICU. Indian J Pediatr 68 11 (2001) 1051-1055
152. Futrakul P., Poshyachinda M., Mitrakul C., Kwakpetoon S., Unchumchoke P., Teranaparin C., et al. Hemodynamic response to high-dose methyl prednisolone and mannitol in severe dengue-shock patients unresponsive to fluid replacement. Southeast Asian J Trop Med Public Health 18 3 (1987) 373-379
153. Lum L., Goh A., Chan P., El-Amin A., and Lam S. Risk factors for hemorrhage in severe dengue infections. J Pediatr 140 (2002) 629-631
154. Tan P.C., Rajasingam G., Devi S., and Omar S.Z. Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome. Obstet Gynecol 111 (2008) 1111-1117
155. Waduge R., Malavige G.N., Pradeepan M., Wijeyaratne C.N., Fernando S., and Seneviratne S.L. Dengue infections during pregnancy: a case series from Sri Lanka and review of the literature. J Clin Virol 37 (2006) 27-33
156. Maroun S.L., Marliere R.C., Barcellus R.C., Barbosa C.N., Ramos J.R., and Moreira M.E. Case report: vertical dengue infection. J Pediatr (Rio J) 84 (2008) 556-559
157. Pediatric Dengue Vaccine Initiative website. Accessed January 9, 2009. www.pdvi.org
158. Hayes J.M., Garcia-Rivera E., Flores-Reyna R., Suarez-Rangel G., Rodriguez-Mata T., Coto-Portillo R., et al. Risk factors for infection during a severe dengue outbreak in El Salvador in 2000. Am J Trop Med Hyg 69 6 (2003) 629-633
159. Heintze C., Velasco Garrido M., and Kroeger A. What do community-based dengue control programmes achieve?. A systematic review of published evaluations. Trans Royal Soc Trop Med Hyg 101 (2007) 317-325
160. McCall P.J., and Lenhart A. Dengue control. Lancet Infect Dis 8 (2008) 7-8
161. Kroeger A., Lenhart A., Ochoa M., Villegas E., Levy M., Alexander N., et al. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomized trials. BMJ 332 7552 (2006) 1247-1252
162. Lenhart A., Orelus N., Maskill R., Alexander N., Streit T., and McCall P.J. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health 13 1 (2008) 56-67
163. Morens D.M., and Fauci D.S. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 299 2 (2008) 214-216
164. Enserink M. Entomology. A mosquito goes global. Science 321 5896 (2008) 864-866
165. Reiter P., Lathrop S., Bunning M., Biggerstaff B., Singer D., Tiwari T., et al. Texas lifestyle limits transmission of dengue virus. Emerg Infect Dis 9 (2003) 86-89
166. Freedman D.O., Weld L.H., Kozarsky P.E., Fisk T., Robins R., von Sonnenburg F., et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 354 2 (2006) 119-130
167. Solomon T. Control of Japanese encephalitis-within our grasp?. N Engl J Med. 355 9 (2006) 869-871
168. Solomon T. Flavivirus encephalitis. N Engl J Med 351 (2004) 370-378
169. Ooi M.H., Lewthwaite P., Lai B.F., Mohan A., Clear D., Lim L., et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in Central Sarawak, Malaysia, 1997-2005. Clin Infect Dis 47 (2008) 458-468
170. Solomon T., Dung N.M., Wills B., Kneen R., Gainsborough M., Diet T.Y., et al. Interferon alfa-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet 361 (2003) 821-826
171. Cardosa M.J., Wang S.M., Sum M.S., and Tio P.H. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol 2 (2002) 9
172. Lacey L.A. Bacillus thuringiensis serovariety israelensis and Bacillus sphaericus for mosquito control. J Am Mosq Control Assoc 23 Suppl 2 (2007) 133-163
173. Teng H.J., Lu L.C., Wu Y.L., and Fang J.G. Evaluation of various control agents against mosquito larvae in rice paddies in Taiwan. J Vector Ecol 30 1 (2005) 126-132
174. Marten G.G., and Reid J.W. Cyclopoid copepods. J Am Mosq Control Assoc 23 Suppl 2 (2007) 65-92
175. Solomon T. New vaccines for Japanese encephalitis. Lancet Neurol 7 (2008) 116-118
176. Fischer M., Casey C., and Chen R. Promise of new Japanese encephalitis vaccines. Lancet 370 (2007) 1806-1808
177. Tauber E., Kollaristch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenecity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial. Lancet 370 (2007) 1847-1853
178. U.S. Centers for Disease Control and Prevention. Japanese Encephalitis Vaccination. Accessed January 9, 2009. http://www.cdc.gov/vaccines/vpd-vac/j-enceph/default.htm
179. Lehtinen V.A., Huhtamo E., Siikamaki H., and Vapalahti O. Case report: Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol 43 (2008) 93-95
180. World Health Organization. Vaccine-preventable diseases and vaccines. In: Wilder-Smith A. (Ed). International Travel and Health, 2008 (2008), World Health Organization, Geneva
181. Ostlund M.R., Kan B., Karlsson M., and Vene S. Japanese encephalitis in a Swedish tourist after traveling to Java and Bali. Scand J Infect Dis 6 -7 (2004) 512-513
182. Centers for Disease Control and Prevention. Japanese encephalitis in a U.S. traveler returning from Thailand, 2004. MMWR 54 (2005) 123-125
183. Jelinek T. Japanese encephalitis vaccine in travelers. Exp Rev Vacc 7 5 (2008) 689-693
184. Reimann C.A., Hayes E.B., Di Guiseppi C., Hoffman R., Lehman J., Lindsey N.P., et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg 79 6 (2008) 974-979
185. Centers for Disease Control and Prevention. West Nile virus activity-United States, 2006. MMWR 56 22 (2007) 556-559
186. Ligon B.L. Reemergence of an unusual disease: the Chikungunya epidemic. Semin Pediatr Infect Dis 17 (2006) 99-104
187. Harley D., Sleigh A., and Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 14 4 (2001) 909-932
188. Suhrbier A., and Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 16 (2004) 374-379
189. de Lamballerie X., Leroy E., Charrel R.N., Ttsetsarkin K., Higgs S., and Gould E.A. Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come?. Virology J 5 (2008) 33-36
190. Vazeille M., Jeannin C., Martin E., Schaffner F., and Failloux A. Chikungunya: a risk for Mediterranean countries?. Acta Tropica 105 (2008) 200-202
191. Charrel R.N., de Lamballerie X., and Raoult D. Chikungunya outbreaks-the globalization of vectorborne diseases. N Engl J Med 356 8 (2007) 769-771
192. Gerardin P., Barau G., Michault A., Bintner M., Randrianaivo H., Choker G., et al. Multidisciplinary prospective study of mother-to-child Chikungunya virus infections on the island of La Reunion. PLoS Med 5 3 (2008) 413-423
193. Renault P., Solet J., Sissoko D., Balleydier E., Larrieu S., Filleul L., et al. A major epidemic of Chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 77 4 (2007) 727-731
194. Borgherini G., Poubeau P., Joussaume A., Gouix A., Cotte L., Michault A., et al. Persistent arthralgia associated with Chikungunya virus: a study of 88 adult patients on Reunion Island. Clin Infect Dis 47 (2008) 469-475
195. Dent A.E., and Kazura J.W. Lymphatic filariasis (Brugia malayi, Brugia timori, Wucheria bancrofti). In: Kliegman R.M., Behrman R.E., Jenson H.B., et al. (Eds). Nelson Textbook of Pediatrics. 18th Edition (2007), Elsevier, Philadelphia (PA)
196. Simonsen P.E. Filariases. In: Cook G.C., and Zumla A.I. (Eds). Manson's Tropical Diseases. 21st Edition (2004), Elsevier, London, England
197. Drugs for parasitic infections. Med Lett Drugs Ther 5 (2007) e1-e15
198. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 21 (2008) 673-681
199. Blackburn B.G., Eigege A., Gotau H., Gerlong G., Miri E., Hawley W.A., et al. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria. Am J Trop Med Hyg 75 4 (2006) 650-655